Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00147498
Status:
COMPLETED
Last Update Posted:
2013-01-30
First Post:
2005-09-02
Brief Title:
Three Dose Levels of CP-690550 Monotherapy Versus Placebo Administered Orally Twice Daily BID for 6 Weeks
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase 2a Randomized Double-Blind Placebo-Controlled Multicenter Study To Compare 3 Dose Levels Of CP-690550 Versus Placebo Administered Orally Twice Daily BID For 6 Weeks In The Treatment Of The Signs And Symptoms Of Subjects With Active Rheumatoid Arthritis
Status:
COMPLETED
Status Verified Date:
2012-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The studys objective is to compare the efficacy of 3 dose levels of oral CP-690550 monotherapy 5 mg 15 mg and 30 mg twice daily BID versus placebo administered over 6 weeks for the treatment of the signs and symptoms of subjects with active rheumatoid arthritis RA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None